{"id":3179,"date":"2014-04-23T06:30:00","date_gmt":"2014-04-23T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/delarsrapport-januari-mars-2014\/"},"modified":"2014-04-23T06:30:00","modified_gmt":"2014-04-23T06:30:00","slug":"delarsrapport-januari-mars-2014","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2014\/","title":{"rendered":"Del\u00e5rsrapport januari \u2013 mars 2014"},"content":{"rendered":"
FORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT OCH REGULATORISKA FRAMG\u00c5NGAR MED XPS\u2122 OCH STEEN SOLUTION\u2122<\/strong><\/div>\n<\/p>\n

F\u00d6RSTA KVARTALET (JAN \u2013 MAR 2014)<\/span><\/span><\/p>\n

\u2022 F\u00f6rs\u00e4ljningen under kvartalet uppgick till 18,3 MSEK (16,3), motsvarande en \u00f6kning om 12 procent i SEK. Oms\u00e4ttnings\u00f6kningen var 10 procent i lokala valutor.<\/span><\/span><\/p>\n

\u2022 R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 3,1 MSEK (3,8) motsvarande en EBITDA marginal om 17 procent.<\/span><\/span><\/p>\n

\u2022 Nettoresultatet uppgick till 1,8 MSEK (2,4), vilket gav ett resultat per aktie om 0,09 SEK (0,12). <\/span><\/span><\/p>\n

\u2022 Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten var -3,3 MSEK (4,0) p\u00e5 grund av f\u00f6r\u00e4ndring i r\u00f6relseskulder -3,6 MSEK och inbetald skatt -2,6 MSEK.<\/span><\/span><\/p>\n

\u2022 STEEN Solution\u2122 och relaterade produkter stod f\u00f6r 24 procent (16) av den totala f\u00f6rs\u00e4ljningen.<\/span><\/span><\/p>\n

\u2022 Den av FDA inkallade expertpanelen r\u00f6stade enh\u00e4lligt, med r\u00f6stsiffrorna 10-0, f\u00f6r att XPS\u2122 System med STEEN Solution\u2122 uppfyller kraven f\u00f6r HDE-godk\u00e4nnande (Humanitarian Device Exemption).<\/span><\/span><\/p>\n

\u2022 XPS\u2122 har erh\u00e5llit CE-m\u00e4rke, vilket m\u00f6jligg\u00f6r f\u00f6rs\u00e4ljning av XPS\u2122 och tillh\u00f6rande eng\u00e5ngsartiklar i Europa.<\/span><\/span><\/p>\n

\u2022 I Turkiet har den f\u00f6rsta lungtransplantationen med en lunga som behandlats med STEEN Solution\u2122-metoden genomf\u00f6rts p\u00e5 Sureyyapasa Teaching Hospital.<\/span><\/span><\/p>\n

\u2022 Barnes Jewish Hospital i St Louis, som \u00e4r en pionj\u00e4r inom lungtransplantation, blir den tionde transplantationskliniken att delta i NOVEL studien. Organ Procurement Organization* (OPO) Mid-America Transplant Services i Missouri har k\u00f6pt en XPS\u2122 f\u00f6r att st\u00e4rka samarbetet mellan transplantationscentra och OPO. Bolaget r\u00e4knar med att under andra kvartalet mot kostnadsteckning forts\u00e4tta placera ut XPS\u2122 p\u00e5 transplantationscentra i USA.<\/span><\/span><\/p>\n<\/p>\n

TELEFONKONFERENS<\/span><\/span><\/p>\n

VD Magnus Nilsson presenterar rapporten vid en telefonkonferens klockan 14:00 onsdagen den 23 april 2014. Telefon: 08-50336434, ange kod 1319928<\/span><\/span><\/p>\n<\/p>\n

G\u00f6teborg 23 april 2014<\/span><\/span><\/p>\n

XVIVO Perfusion AB (publ)
Magnus Nilsson, VD<\/span><\/span><\/p>\n

* En OPO eller Organ Procurement Organization \u00e4r ansvarig f\u00f6r samordning och utv\u00e4rdering av donerade organ f\u00f6r organtransplantation i en region i USA.<\/span><\/span><\/p>\n

\n

F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n

Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: christoffer.rosenblad@xvivoperfusion.com<\/a>
F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/a><\/span><\/p>\n

XVIVO Perfusion\u00a0\u00e4r skyldigt att offentligg\u00f6ra informationen i detta pressmeddelande enligt lagen om v\u00e4rdepappersmarknaden och\/eller lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r publicering den\u00a023\u00a0april 2014 kl. 08:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

FORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT OCH REGULATORISKA FRAMG\u00c5NGAR MED XPS\u2122 OCH STEEN SOLUTION\u2122 F\u00d6RSTA KVARTALET (JAN \u2013 MAR 2014) \u2022 F\u00f6rs\u00e4ljningen under…<\/p>\n","protected":false},"template":"","class_list":["post-3179","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q1"],"acf":[],"yoast_head":"\nDel\u00e5rsrapport januari \u2013 mars 2014 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2014\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Del\u00e5rsrapport januari \u2013 mars 2014 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"FORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT OCH REGULATORISKA FRAMG\u00c5NGAR MED XPS\u2122 OCH STEEN SOLUTION\u2122 F\u00d6RSTA KVARTALET (JAN \u2013 MAR 2014) \u2022 F\u00f6rs\u00e4ljningen under...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2014\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2014\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2014\\\/\",\"name\":\"Del\u00e5rsrapport januari \u2013 mars 2014 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2014-04-23T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2014\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2014\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2014\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Del\u00e5rsrapport januari \u2013 mars 2014\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Del\u00e5rsrapport januari \u2013 mars 2014 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2014\/","og_locale":"en_US","og_type":"article","og_title":"Del\u00e5rsrapport januari \u2013 mars 2014 - XVIVO","og_description":"FORTSATT STARK F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT OCH REGULATORISKA FRAMG\u00c5NGAR MED XPS\u2122 OCH STEEN SOLUTION\u2122 F\u00d6RSTA KVARTALET (JAN \u2013 MAR 2014) \u2022 F\u00f6rs\u00e4ljningen under...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2014\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2014\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2014\/","name":"Del\u00e5rsrapport januari \u2013 mars 2014 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2014-04-23T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2014\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2014\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2014\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Del\u00e5rsrapport januari \u2013 mars 2014"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}